News

CBPE Capital Invests In Blatchford

CBPE Capital (“CBPE”) has invested to acquire a majority ownership position in Blatchford, a world leading provider of advanced prosthetic and orthotic (“P&O”) devices.  CBPE will be investing alongside fourth generation family member Stephen Blatchford and the management team led by Adrian Stenson, CEO. Terms of the transaction have not been disclosed.

Blatchford provides highly innovative, premium quality prosthetic and orthotic devices to lower-limb patients across the world. Over 80% of product sales are outside of the UK. As well as designing, manufacturing and distributing products, Blatchford also operates clinical service centres in the UK and Norway, providing valuable patient feedback into the research and development process for new products.

The company will continue its dedication to and focus on developing innovative products that lead to improved clinical outcomes and enhanced quality of life for patients.  The ongoing investment in R&D, under the stewardship of Professor Sir Saeed Zaheedi, has resulted in pioneering prosthetics such as Linx, the world’s first and only truly integrated microprocessor-controlled limb system. This patient-centric culture extends into the clinical divisions of Blatchford where patients receive market-leading, quality rehabilitation services.

CBPE will support management’s plans to bring a range of innovative new products to market and to expand the business geographically, both organically and through acquisitions.

The investment in Blatchford continues CBPE’s successful track record of investing in and developing market-leading, high-growth healthcare businesses. The current portfolio includes Rodericks, a leading provider of dental services, SpaMedica, a leading provider of ophthalmic services, OH Assist, the largest occupational health services provider in the UK, Medica Reporting which is the UK market leader in teleradiology, and Assisted Reproduction & Gynaecology Centre (ARGC) the leading fertility clinic in the UK.

Naveen Passi, Director, CBPE said: “Blatchford provides life-changing products and is a technology-leader in the P&O field. Stephen and Adrian have led the business through a period of substantial growth and we are delighted to be supporting the business in the next phase of its development.”

Adrian Stenson, CEO of Blatchford said: “In CBPE we have found an investor that shares our values, has taken the time to understand the direct effect we have on people’s lives and will help us build our brand and what we stand for on the global stage. CBPE has a track record of successful direct investment in the healthcare area and we look forward to working as a close team to continue delivering exceptional outcomes for patients and stakeholders alike.”

CBPE’s investment in Blatchford was led by Naveen Passi and Ian Moore with support from Rupert Parker and Aqil Sohail. Naveen Passi and Ian Moore will join the Board of Blatchford.

CBPE Capital (“CBPE”) has invested to acquire a majority ownership position in Blatchford, a world leading provider of advanced prosthetic and orthotic (“P&O”) devices.  CBPE will be investing alongside fourth generation family member Stephen Blatchford and the management team led by Adrian Stenson, CEO. Terms of the transaction have not been disclosed.

Blatchford provides highly innovative, premium quality prosthetic and orthotic devices to lower-limb patients across the world. Over 80% of product sales are outside of the UK. As well as designing, manufacturing and distributing products, Blatchford also operates clinical service centres in the UK and Norway, providing valuable patient feedback into the research and development process for new products.

The company will continue its dedication to and focus on developing innovative products that lead to improved clinical outcomes and enhanced quality of life for patients.  The ongoing investment in R&D, under the stewardship of Professor Sir Saeed Zaheedi, has resulted in pioneering prosthetics such as Linx, the world’s first and only truly integrated microprocessor-controlled limb system. This patient-centric culture extends into the clinical divisions of Blatchford where patients receive market-leading, quality rehabilitation services.

CBPE will support management’s plans to bring a range of innovative new products to market and to expand the business geographically, both organically and through acquisitions.

The investment in Blatchford continues CBPE’s successful track record of investing in and developing market-leading, high-growth healthcare businesses. The current portfolio includes Rodericks, a leading provider of dental services, SpaMedica, a leading provider of ophthalmic services, OH Assist, the largest occupational health services provider in the UK, Medica Reporting which is the UK market leader in teleradiology, and Assisted Reproduction & Gynaecology Centre (ARGC) the leading fertility clinic in the UK.

Naveen Passi, Director, CBPE said: “Blatchford provides life-changing products and is a technology-leader in the P&O field. Stephen and Adrian have led the business through a period of substantial growth and we are delighted to be supporting the business in the next phase of its development.”

Adrian Stenson, CEO of Blatchford said: “In CBPE we have found an investor that shares our values, has taken the time to understand the direct effect we have on people’s lives and will help us build our brand and what we stand for on the global stage. CBPE has a track record of successful direct investment in the healthcare area and we look forward to working as a close team to continue delivering exceptional outcomes for patients and stakeholders alike.”

CBPE’s investment in Blatchford was led by Naveen Passi and Ian Moore with support from Rupert Parker and Aqil Sohail. Naveen Passi and Ian Moore will join the Board of Blatchford.